Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mast Cell Activation Disorder Idiopathic”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Not applicableStudy completedNCT03406325
What this trial is testing

Mast Cell Activation Test in Allergic Disease

Who this might be right for
AsthmaMastocytosisMast Cell Activation Syndrome+4 more
Hong Kong Sanatorium & Hospital 19
Not applicableWithdrawnNCT00499668
What this trial is testing

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Who this might be right for
Myeloproliferative DisordersLeukemiaLymphoma+5 more
Vanderbilt-Ingram Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00255346
What this trial is testing

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromesAgnogenic Myeloid Metaplasia+5 more
M.D. Anderson Cancer Center 68
Not applicableStudy completedNCT00047918
What this trial is testing

Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing

Who this might be right for
MastocytosisAnaphylaxis
National Institute of Allergy and Infectious Diseases (NIAID) 100
Testing effectiveness (Phase 2)Ended earlyNCT05652907
What this trial is testing

Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

Who this might be right for
Mast Cell Activation SyndromeMast Cell Activation Disorder Idiopathic
Quantum Biopharma 2
Testing effectiveness (Phase 2)Ended earlyNCT00387426
What this trial is testing

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in Remission+29 more
National Cancer Institute (NCI) 14